ConductScience.org, home

Paper17699786

Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.

Ogino A and 9 others. Cancer Res, 2007. Cited by 167 papers, by iCite.

Cite this record

ConductScience Library. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Papers, record 17699786. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17699786

Download JSON
Cell line
RPC-91 paper
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
PubMed
Journal
Cancer Res
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
167
iCite
Relative citation ratio, by iCite
3.04
iCite
Revised in PubMed
2022-04-08
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ogino AAtsuko
2Kitao HHiroyuki
3Hirano SSeiki
4Uchida AAkiko
5Ishiai MMasamichi
6Kozuki TToshiyuki
7Takigawa NNagio
8Takata MMinoru
9Kiura KKatsuyuki
10Tanimoto MMitsune

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
ErbB ReceptorsMajor topic
Lung NeoplasmsMajor topic
MutationMajor topic
QuinazolinesMajor topic
Adenocarcinoma
Cell Line, Tumor
Drug Resistance, Neoplasm
Gefitinib
Humans
Phosphorylation
Protein Kinase Inhibitors
Receptor, ErbB-3

Source PubMed

Download CSV of topics

Cited by95

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 167 citations.

PMIDTitleJournalYearIn PapersSource
41599648Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41599648PubMed
41535280EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge.Nat Commun2026https://conductscience.org/library/papers/41535280PubMed
41510378Targeting ferroptosis to overcome drug resistance in lung cancer.Transl Lung Cancer Res2025https://conductscience.org/library/papers/41510378PubMed
41222695CRISPR screens reveal YAP/TEAD axis as a mediator of drug-tolerant cells in EGFR-mutant NSCLC.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41222695PubMed
40323013APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer.Cancer Res Commun2025https://conductscience.org/library/papers/40323013PubMed
39138145Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39138145PubMed
39122703Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer.Cell Death Dis2024https://conductscience.org/library/papers/39122703PubMed
39041204Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor-Tolerant Cells in NSCLC Patient-Derived Xenografts.Cancer Res Commun2024https://conductscience.org/library/papers/39041204PubMed
38658677Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.Commun Biol2024https://conductscience.org/library/papers/38658677PubMed
37111291Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present).Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37111291PubMed
36028467Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment.Cancer Sci2022https://conductscience.org/library/papers/36028467PubMed
35605028APE1 shRNA-loaded cancer stem cell-derived extracellular vesicles reverse Erlotinib resistance in non-small cell lung cancer via the IL-6/STAT3 signalling.Clin Transl Med2022https://conductscience.org/library/papers/35605028PubMed
35408854Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth.Int J Mol Sci2022https://conductscience.org/library/papers/35408854PubMed
34830794Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.Cancers (Basel)2021https://conductscience.org/library/papers/34830794PubMed
34702990Harnessing the predictive power of preclinical models for oncology drug development.Nat Rev Drug Discov2022https://conductscience.org/library/papers/34702990PubMed
34692766ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non-Small-Cell Lung Cancer: A Multi-Center Retrospective Study.Front Mol Biosci2021https://conductscience.org/library/papers/34692766PubMed
34590051A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood.JTO Clin Res Rep2021https://conductscience.org/library/papers/34590051PubMed
34518338Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development.Cold Spring Harb Perspect Med2021https://conductscience.org/library/papers/34518338PubMed
34396444Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.Mol Med Rep2021https://conductscience.org/library/papers/34396444PubMed
34386061Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression.Oncol Lett2021https://conductscience.org/library/papers/34386061PubMed

See all 95 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
MAPK35595PubTator's text mininghttps://conductscience.org/library/genes/5595NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17699786

GET https://conductscience.org/api/papers/v1/17699786/cited_by?page=2